Crossmark

Adjuvant Glucose-Like Peptide 1 Receptor Agonist Therapy for Suboptimal Weight Loss After Bariatric Surgery: a Systematic Review

Published Online: 2024-03-04

Published Print: 2024-05

Authors

Dréant, Alexandre

Blanchard, Claire

Jacobi, David https://orcid.org/0000-0001-8674-223X
License Information

Text and Data Mining valid from 2024-03-04

Version of Record valid from 2024-03-04
More Information

Article History

Received: 29 November 2023

Revised: 21 February 2024

Accepted: 22 February 2024

First Online: 4 March 2024

Declarations

:

: This article does not contain any studies with human participants or animals performed by any of the authors.

: Informed consent does not apply.

: David Jacobi has served on advisory boards for Novo Nordisk, Eli Lilly, and Pfizer. Claire Blanchard has received speaker’s fees from Novo Nordisk.

Document is current